Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

ADAPTIMMUNE THERAPEUTICS PLC

(ADAP)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Business Summary
Logo Adaptimmune Therapeutics plc
Adaptimmune Therapeutics plc is a clinical-stage biopharmaceutical company. The Company is focused on cancer immunotherapy products based on its Specific Peptide Enhanced Affinity Receptor (SPEAR) T-cell platform. Its SPEAR T-cell platform enables it to identify cancer targets, find and genetically engineer T-cell receptors (TCRs) against those targets, and produce therapeutic candidates (SPEAR T-cells) for administration to patients. The Company engineers TCRs to increase the affinity to cancer specific peptides in order to destroy cancer cells in patients. The CompanyÔÇÖs product pipeline includes ADP-A2M4, ADP-A2M4CD8, ADP-A2AFP and ADP-A2M10. Its ADP-A2M4 (MAGE-A4) SPEAR T-cell therapy is directed to a member of the MAGE family of cancer testis antigen expressed in a number of solid tumor cell types.

Number of employees : 462 people.
Sales per Business
20192020Delta
Development1.1299.6%3.9699.2% +252.76%
USD in Million
Sales per region
20192020Delta
United Kingdom1.1299.6%3.9699.2% +252.76%
USD in Million
Managers
Name Title Age Since
Adrian Rawcliffe Chief Executive Officer & Director 48 2019
Gavin Wood Chief Financial Officer 50 2020
Elliot Norry, Dr. Chief Medical Officer 57 -
William C. Bertrand Chief Operating Officer 55 2017
Lawrence M. Alleva Independent Non-Executive Director 69 2015
Charles Elliott Sigal, Dr. Independent Non-Executive Director 68 2015
David M. Mott Chairman 54 2017
Ali Behbahani, Dr. Independent Non-Executive Director 44 2014
Barbara Gayle Duncan Independent Non-Executive Director 55 2016
Tal Zaks Independent Non-Executive Director 54 2016
Members of the board
Name Title Age Since
David M. Mott Chairman 54 2017
James Julian Noble Non-Executive Director 61 2019
Adrian Rawcliffe Chief Executive Officer & Director 48 2019
Lawrence M. Alleva Independent Non-Executive Director 69 2015
Charles Elliott Sigal, Dr. Independent Non-Executive Director 68 2015
Ali Behbahani, Dr. Independent Non-Executive Director 44 2014
Barbara Gayle Duncan Independent Non-Executive Director 55 2016
Tal Zaks Independent Non-Executive Director 54 2016
John P. Furey Independent Non-Executive Director 55 2018
Equities
Vote QuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 932,984,520 67,500,000 7.2% 0 0.0% 7.2%
Shareholders
NameEquities%
Capital Research & Management Co. (World Investors) 9,323,900 6.00%
Baillie Gifford & Co. 8,448,418 5.43%
Victory Capital Management, Inc. (Investment Management) 2,159,580 1.39%
Bessemer Investment Management LLC 1,772,269 1.14%
BlackRock Fund Advisors 890,970 0.57%
Rafferty Asset Management LLC 819,115 0.53%
Wellington Management Co. LLP 492,007 0.32%
Fidelity Management & Research Co. LLC 491,600 0.32%
JPMorgan Asset Management (UK) Ltd. 296,790 0.19%
SSgA Funds Management, Inc. 257,402 0.17%
Company contact information
Adaptimmune Therapeutics Plc
60 Jubilee Avenue
Milton Park
Abingdon, Oxfordshire OX14 4RX

Phone : +44.1235.430000
Fax : +44.1235.430001
Web : http://www.adaptimmune.com